Try our beta test site
7 studies found for:    "Sound Pharmaceuticals"
Show Display Options
Rank Status Study
1 Enrolling by invitation Study to Evaluate SPI-1005 in Adults With Meniere's Disease
Condition: Meniere's Disease
Intervention: Drug: SPI-1005
2 Not yet recruiting A Phase 2b Study of SPI-1005 to Reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss
Condition: Noise Induced Hearing Loss
Interventions: Drug: SPI-1005 200mg;   Drug: SPI-1005 400mg;   Drug: Placebo
3 Not yet recruiting SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity
Condition: Ototoxicity
Interventions: Drug: Placebo;   Drug: SPI-1005 Ebselen 200mg Capsule x1;   Drug: SPI-1005 Ebselen 200mg Capsule x2;   Drug: SPI-1005 Ebselen 200mg Capsule x3
4 Not yet recruiting SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Conditions: Lung Cancer;   Head and Neck Cancer;   Hearing Loss;   Ototoxicity;   Tinnitus;   Neuropathy
Interventions: Drug: SPI-1005 Low Dose;   Drug: SPI-1005 Middle Dose;   Drug: SPI-1005 High Dose;   Drug: Placebo
5 Completed Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
Condition: Temporary Auditory Threshold Shift
Interventions: Drug: SPI-1005 Low dose;   Drug: SPI-1005 Middle dose;   Drug: SPI-1005 High dose;   Drug: Placebo
6 Completed Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
Conditions: Hearing Loss;   Cancer
Interventions: Drug: SPI-1005;   Drug: Placebo
7 Not yet recruiting Ebselen as an add-on Treatment in Hypo/Mania
Conditions: Bipolar Disorder;   Bipolar Disorder, Manic
Interventions: Drug: Ebselen;   Drug: Placebo Oral Capsule

Study has passed its completion date and status has not been verified in more than two years.